Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleDramatic improvement of refractory Isaacs' syndrome after treatment with dronabinol.
Author(s)Meyniel C, Ollivier Y, Hamidou M, Péréon Y, Derkinderen P.
Journal, Volume, IssueClin Neurol Neurosurg. 2011 May;113(4):323-4.
Major outcome(s)Dramathic improvement of symptoms (profuse sweating, muscular twitching, weight loss)
IndicationAbstract
MedicationDelta-9-THC

no abstract available.

Summary from the IACM-Bulletin:

According to a case report from a hospital in Nantes, France, oral THC (dronabinol) improved the symptoms of a patient with Isaacs' syndrome, which did not respond to other treatments. A 56-year-old man presented with episodes of profuse sweating associated with muscular twitching that began one year before the first assessment in the hospital. Bouts of drenching sweats occurred 2 or 3 times a day, lasted from 20 minutes to 2 hours and were associated with intense itching on body truck. Body weight had decreased from 70 to 55 kg during that period. He presented with prominent generalized myokymia, i.e. involuntary, spontaneous, localized quivering of a few muscles bundles within a muscle. Antibodies to transmembrane channels specific for potassium were highly increased. Several medications and treatments, including intravenous immunoglobulins, were tried to reduce symptoms, but were all ineffective. Finally, THC was titrated up progressively to 20 mg/day over a one month period and used as a monotherapy.

Three months after the initiation of the treatment, the patient started to improve. After one year, myokymia completely disappeared, there were no longer any sweating attacks and body weight increased to 65 kg. In addition, antibodies to potassium channels were normal. Authors noted that "the dramatic improvement lasted for the last 2 years and is still ongoing." Isaacs' syndrome, also called neuromyotomia or continuous muscle fibre activity, is a peripheral motor nerve hyperactivity disorder. It is usually regarded as an autoimmune disease caused by antibodies against neuromuscular junction, resulting in an increase in neurotransmitter release. Authors think that "the mechanism of action of dronabinol was rather immunomodulatory than symptomatic."

Route(s)Oral
Dose(s)20 mg
Duration (days)700
Participants1 patient with Isaacs' syndrome
DesignUncontrolled case report
Type of publicationMedical journal
Address of author(s)CHU Nantes, Department of Neurology, Nantes F-44093, France; Nantes University, Nantes F-44093, France.
Full text

[Back to Overview]  [IACM Homepage]


up